Healthcare

Addiction Biotech Cannabis Genetics Healthcare Medical Devices Pharmaceutical Science Veterinary
News Release Digital Asset Direct

Breakthroughs in roofing for residential clean energy, non-flammable safer batteries, people struggling with hearing loss coming to ShowStoppers press event during CES

ShowStoppers

Tech and business journalists will see breakthroughs in roofing for residential clean energy, safer batteries than lithium ion, and medical-grade hearing earbuds, at ShowStoppers® at CES, the press event scheduled for 5 Jan. 2022 during the CES tradeshow in Las Vegas. For press registration, please contact Steve Leon, mailto:sl@showstoppers.com, +1 310-936-8530. “The world’s first true solar residential roof” is coming to shake up the entire industry. Nanotech Energy, https://nanotechenergy.com, a CES 2022 Innovation Award Winner and the only producer of non-flammable, graphene-based batteries on the market, will show batteries that are infinitely safer and higher performing than the industry-standard, highly-flammable lithium-ion batteries that power consumer electronics and electric vehicles but can suddenly catch fire or explode. Jabra, https://www.jabra.com, a world-leading audio and video pioneer, flexes its engineering excellence with several new products, including the Jabra Enhance Plus, a medical-grade hearing solution with advanced audio engineering for better conversations, music, and calls. Also, their latest True Wireless Earbuds will be on display. The ShowStoppers press event organizes product launches, sneak previews and hands-on demonstrations of new tech for work, home and play for journalists, industry and financial analysts, venture capitalists and business executives -- from AI to 5G to cloud, VR to digital health; to better, safer, healthier tools for working from home or going back to the office; to future mobility and autonomy, robotics or smart cities; to apps and hardware that drive mobile and desktop innovation; to wearables, IoT, appliances, entertainment, and more. About ShowStoppers Now in its 26th year, ShowStoppers, https://www.showstoppers.com/, is the global leader in producing press and business events spanning the U.S., Europe and Asia. Each event organizes product launches, sneak previews and demonstrations for selected journalists, bloggers, industry and financial analysts, venture capitalists and business executives. Industry leaders, innovators and startups exhibit to generate news coverage and product reviews, make new connections, promote brand and open new markets. ShowStoppers produces official press events at CE Week, IFA and NAB; partners with CTA, IFA, GSMA and CEATEC; and produces events during CES, IFA, MWC, NAB, CE Week, CEATEC and other tradeshows. ShowStoppers streams online, broadcasting live events, month after month. To learn more about how you and your company can meet the press at ShowStoppers press events in person and online at ShowStoppers TV, contact Lauren Merel, m a ilto:lauren@showstoppers.com, +1 908-692-6068, or Dave Leon, mailto:dave@showstoppers.com, +1 845-821-6123. Contact Details Steve Leon +1 310-936-8530 sl@showstoppers.com Company Website https://showstoppers.com

December 28, 2021 09:45 AM Eastern Standard Time

New research shows how combining anxiety medications and opioids can be risky for elderly patients

Patient Safety Authority

A new analysis from the Patient Safety Authority (PSA) demonstrates that despite the documented risks, benzodiazepines are used together with opioid pain medications among patients aged 65 and older in the hospital setting. The combination can cause changes in mental status, breathing, heart rate and blood pressure. In two-thirds of cases studied, a reversal agent was required to treat the reaction. The report is published in the December 2021 issue of PATIENT SAFETY. Researchers at the Patient Safety Authority reviewed 80 patient safety reports from January through December 2020 from 39 facilities throughout Pennsylvania. The most common adverse drug reactions (ADRs) related to this combination of medications occurred in the surgical, imaging/ diagnostic and medical-surgical care areas. The cases studied are from the Pennsylvania Patient Safety Reporting System, the largest database of its kind in the United States. “The problem may be much larger than it appears,” says executive director, Regina Hoffman, MBA, RN. “Many ADRs go unreported, so we believe our analysis likely only includes a fraction of those related to the combination of benzodiazepines and opioids with elderly patients. Our goal is to make providers more aware of the risks. We hope they may re-evaluate their prescribing habits and facility practices and move toward safer patient care for this vulnerable population.” Other topics in this issue of PATIENT SAFETY include: Emergence delirium and patient risk: what can we do? – Patient Safety Authority researchers offer a data analysis of safety events related to perioperative delirium and offer a four-phase intervention package to reduce risk to patients and providers. COVID nurses and PTSD - Just when we need them most, many nurses caring for patients on the front lines feel abandoned and expendable. Cassandra Alexander relates the toll the daily struggle has taken on her mental health—a sobering glimpse at the experiences of nurses like her around the country. Atrial fibrillation and cancellations - New-onset atrial fibrillation can pose a significant patient safety risk during the perioperative period. The Patient Safety Authority examines the impact and opportunities for improvement in ambulatory surgical facilities. Fixing healthcare: how activated patients can guide us forward – One critical way to make healthcare safer is to involve the patients themselves. What does it mean to be activated and how may it save your life? Patient engagement expert Dr. Judith Hibbard explains the importance and how to do it. A study and a toolkit to reduce urinary tract infections (UTIs) in long-term care facilities - UTIs are common in long-term care facilities, but they’re notoriously difficult to diagnose. The Patient Safety Authority analyzed trends in rates, infection types and treatments. Researchers offer a toolkit they developed to help reduce the occurrence of UTIs and promote antibiotic stewardship. PATIENT SAFETY is the peer-reviewed journal of the Patient Safety Authority. A scientific publication, PATIENT SAFETY humanizes patient harm with stories, opinion pieces, and magazine-quality design. It has a readership of more than 45,000 people in 164 countries. About PSA Established under the Medical Care Availability and Reduction of Error (MCARE) Act of 2002, the PSA, an independent state agency, collects and analyzes patient safety data to improve safety outcomes and help prevent patient harm. http://patientsafety.pa.gov/ Contact Details Bev Volpe +1 609-230-4696 bev@madisongall.com Company Website http://patientsafety.pa.gov/

December 21, 2021 11:43 AM Eastern Standard Time

Image

Revolutionizing the Way We Pay for Healthcare: Can Tech Give You Freedom from Health Insurance?

YourUpdateTV

Every year, a quarter million Americans declare bankruptcy due to medical bills despite having health insurance. Recently, Andy Schoonover, Founder and CEO of CrowdHealth, teamed with YourUpdateTV on a satellite media to discuss how leveraging technology can help you get your healthcare freedom back without breaking the bank. A video accompanying this announcement is available at: https://youtu.be/7HLiYcpGqFU For 30 years, the middle class has experienced no real income growth due to the increasing costs of health insurance. Research shows inadequate health insurance accounts for nearly 67 percent of all bankruptcies. This statistic is staggering and illustrates a difficult reality for the many American families navigating today’s insurance market. Technology is being used to build a new, community-powered solution for all. CrowdHealth is an app and technology platform that allows you to make a monthly contribution to the Community and those funds are used to fund the community’s health care bills. Crowdfunding models of paying for health care maximize the probability that all members’ eligible bills will be paid in full each month. These models come without the burdens of skyrocketing premiums and deductibles. Unlike traditional models, members aren’t chained to yearly contracts and have more flexibility and autonomy with crowdfunded models. CrowdHealth provides app-based tools such as: The latest innovation in fintech, allowing their members to aggregate crowdsourced funds to pay doctors quickly and directly. A nationwide doctor quality and cost database that empowers their members to make informed decisions about their care without the limitation of restrictive networks. Highly engaged, personalized Care Advocacy to help their members navigate their health journeys. Negotiation and legal services that fight for patients when dealing with outrageous bills. Access to deeply discounted prescription drugs. By eliminating insurance plan middlemen, reimagining the healthcare payment system and empowering doctors to direct care choices, CrowdHealth will help their members significantly reduce their out-of-pocket expenses when compared to healthcare.gov plans. To learn more about CrowdHealth go to joincrowdhealth.com. About Andy Schoonover Andy Schoonover is founder and CEO of CrowdHealth, a community-powered alternative to health insurance that provides a revolutionary way of paying for healthcare bills through crowdfunding. Schoonover was previously CEO of VRI, a healthcare technology company focused on monitoring patients with chronic conditions out of their homes. He is a graduate of the University of Virginia and Stanford University’s Graduate School of Business About YourUpdateTV: YourUpdateTV is a social media video portal for organizations to share their content. It includes separate channels for Health and Wellness, Lifestyle, Media and Entertainment, Money and Finance, Social Responsibility, Sports and Technology. Contact Details YourUpdateTV +1 212-736-2727 yourupdatetv@gmail.com

December 20, 2021 05:00 PM Eastern Standard Time

Video

Record 40,000 Transplants Honors Legacy of Donors

United Network for Organ Sharing

Today, Dec. 17, 2021, the United States has officially surpassed 40,000 transplants in one year, a historic first for the nation. This is according to United Network for Organ Sharing (UNOS), the engine that powers the national organ donation and transplantation system under contract with the federal government. 2020 marked the 10th consecutive record-breaking year for organ donations from deceased donors and the 8th in a row for deceased donor transplants. “Reaching 40,000 organs transplants in a single year is a testament to the lifesaving work being done day in and day out that makes our donation and transplantation system the highest performing in the world,” said Matthew Cooper, M.D., president of the UNOS Board of Directors. "It is also a testament to the generosity of so many inspiring donors and their courageous families who gave the gift of life. “This news serves as a reminder that no matter what challenges we face as a nation, our community of doctors, patients, donor families, hospitals, organ procurement professionals, and advocates are dedicated to building on past successes to save even more lives. But there is always more work to do.” As of today, 106,962 men, women and children are on the waiting list for a transplant, which is at the lowest it has been since 2009. The list topped 124,000 at its height in 2014. "Every one of us has the potential to save multiple lives by registering to be an organ, tissue and eye donor," Cooper said. Learn more about organ donation and transplantation and how to register to be a donor at www.unos.org. Matthew Cooper, M.D., FACS, is president of the UNOS Board of Directors, Director of Kidney and Pancreas Transplantation at MedStar Georgetown Transplant Institute at MedStar Georgetown University Hospital, and a professor in the department of surgery at Georgetown University School of Medicine. ### About United Network for Organ Sharing United Network for Organ Sharing (UNOS) is a non-profit, charitable organization that serves as the Organ Procurement and Transplantation Network (OPTN) under contract with the federal government. The OPTN helps create and define organ allocation and distribution policies that make the best use of donated organs. This process involves continuously evaluating new advances and discoveries so policies can be adapted to best serve patients waiting for transplants. All transplant programs and organ procurement organizations throughout the country are OPTN members and are obligated to follow the policies the OPTN creates for allocating organs. Contact Details United Network for Organ Sharing Eric Steigleder +1 804-782-4730 eric.steigleder@unos.org Company Website https://unos.org

December 17, 2021 06:43 PM Eastern Standard Time

Image

METER Group Unveils Major Update to AQUALAB Vapor Sorption Analyzer Software

METER Group, Inc.

Moisture Analysis Toolkit enables food and pharma manufacturers to address ingredient source changes, accelerate product formulation, extend shelf life, and employ the most cost-effective packaging using research-tested predictive models that present complex isotherm and water activity data as clear, actionable insights METER Group, Inc. USA (METER) today unveiled a major update to the AQUALAB Vapor Sorption Analyzer (VSA) Moisture Analysis Toolkit, enabling food and pharma companies to harness analytics and predictive modeling that accelerates product formulation, maximizes cost-efficiency of packaging, and extends shelf life. The AQUALAB VSA Moisture Analysis Toolkit (MAT) is a first-of-its-kind, intuitive, full-featured modeling solution that transforms moisture data into solutions using research-tested predictive models. This software helps overcome key water-related research and development challenges. It is particularly relevant as food manufacturers turn to high-tech solutions to increase profitability in the face of supply chain issues and consumer concern over safety and sustainability. Like most manufacturers, food producers are increasingly impacted by supply chain shortages. The pandemic has exacerbated existing ingredient sourcing problems caused by climate change. With the Moisture Analysis Toolkit, manufacturers can use high-resolution moisture data to predict the effect of new ingredient candidates on moisture in the final product. “In a new supplier situation, our clients rely on the toolkit to make faster decisions and react quickly to new ingredient sourcing,” says METER Executive Vice President Takuya Ohki. “That’s what the toolkit is all about—faster, data-driven decisions that allow our clients to stay competitive in a fast-changing marketplace.” Ohki says that data-driven decision making is at the heart of the MAT, which includes tools for selecting the correct packaging and determining shelf life. “Historically, companies have tended to over-package and set a conservative best-by date. Now consumers are pushing companies to address issues of 30-40 percent waste in the food supply—while still demanding a mold-free product. Tackling safety and sustainability in tandem requires our best use of science. Too much of this research is still not implemented in industry. The Moisture Analysis Toolkit is something designed to make this science immediately accessible, to allow food manufacturers to solve these problems today.” The MAT takes advantage of a unique moisture map created by METER Group’s AQUALAB VSA. The VSA generates a high-resolution isotherm called a Dynamic Dewpoint Isotherm (DDI) curve. DDI curves can save companies months spent identifying a critical water activity in low and intermediate moisture food and pharmaceutical products, because they clearly illustrate the change in sorption properties. While competitor instruments use just the DVS method, METER Group’s MAT not only delivers DVS isotherms, but it also provides truly dynamic high-resolution DDI isotherm curves, uncovering granular details which have never been seen before. Unlocking access to these critical insights allows for more precise formulation, more accurate predictions, and more complete product knowledge. The business benefits and value are significant. For example, a dry ingredients company struggling with excessive labor, time, and space spent on shelf-life studies reduced the amount of physical shelf-life tests by 75 percent, cutting expenditures on testing from $300,000 to less than $50,000 per year. METER’s Moisture Analysis Toolkit also lets manufacturers work backward, picking a final water activity that maximizes shelf life and then getting guidance on specific formulation decisions around ingredient selection. This not only makes the formulation process more precise, but also speeds it up. A cold press bar company used the MAT with VSA-generated DDI isotherms to assess moisture migration during the R&D process, allowing them to release new products 5x faster and bring new flavors to market before competitors. “We see our clients succeeding from a profitability standpoint, but to me, that’s only part of the equation,” says Ohki. “The Moisture Analysis Toolkit empowers food and pharma companies to eliminate waste and inefficiencies across their respective supply chains on an unprecedented scale. That’s about more than profitability—it’s about putting existing science to work on the big problems we have to tackle as a society.” About METER Group METER Group, a Decagon and UMS combined company, delivers real-time, high-resolution data that fuels production and processes for the food quality, environmental research, urban and agriculture sectors. Through the power of its employees, METER combines science, engineering, and design expertise to turn physical measurements into useful information. Learn more at www.metergroup.com. Contact Details JMRConnect Mostafa Razzak +1 202-904-2048 m.razzak@jmrconnect.net

December 16, 2021 08:30 AM Eastern Standard Time

Lind to Provide $5M to Boost Prizma Sales to the Growth in Demand for Covid-19 Testing Across California

G Medical Innovations Holdings

TEL AVIV and NEW YORK, Dec. [16], 2021 G Medical Innovations Holdings Ltd. (NASDAQ: GMVD) (the "Company") today announced the pricing of a private placement in the form of a convertible note in the principal amount of $5,000,000 that has a two-year maturity and a fixed conversion price. Proceeds to be used to launch 25 Covid-19 testing centers in California in Q1, 2022. The first six locations are currently in operation as of Wednesday, December 15, 2021. G Medical Innovations Holdings Ltd., a telehealth, medical device, and remote patient monitoring company providing clinical-grade solutions for consumers, medical professionals, and healthcare institutions, Known for its groundbreaking technology, remote patient monitoring devices and services utilized by hospitals and cardiologists across the country, GMedical’s innovative Prizma monitoring device will be offered direct-to consumer for the first time at these testing locations, as part of an aggressive company direct-to-consumer strategy. Prizma is a user-friendly cell phone-sized device that can help monitor user’s vital signs, providing to-the-minute readings for ECG, temperature, oxygen saturation, heart rate, stress levels and blood pressure, help track body weight and glucose levels. Data is presented directly to the user and the designated care provider. Prizma can also be prescribed by physicians to patients with cardiac or respiratory disease, diabetes and other health issues. With the explosive growth in demand for Covid testing across the country, G Medical expects its new California locations to boost Prizma sales. “By offering Prizma at our Covid19 testing sites we are empowering consumers to measure and monitor their vital signs post testing, in the comfort of their own home,” said G Medical CEO Dr. Yacov Geva. “This unique opportunity to introduce our Prizma device to customers face-to-face at the point of sale is an important step forward in our company’s direct-to-consumer initiative EF Hutton, division of Benchmark Investments, LLC, acted as exclusive placement agent for the offering. This press release shall not constitute an offer to sell or the solicitation of an offer to buy any of the securities described herein, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction. Forward-looking Statements This press release contains forward-looking statements within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995 and other Federal securities laws. Words such as “expects,” “anticipates,” “intends,” “plans,” “believes,” “seeks,” “estimates” and similar expressions or variations of such words are intended to identify forward-looking statements. Because such statements deal with future events and are based on G Medical’s current expectations, they are subject to various risks and uncertainties, and actual results, performance or achievements of G Medical could differ materially from those described in or implied by the statements in this press release. For example, G Medical is using forward-looking statements when it discusses the use of proceeds from the private placement, plans to open as many as 25 Covid-19 testing centers in California in Q1, 2022, its direct-to-consumer strategy and the benefits and advantages of its Prizma medical device. The forward-looking statements contained or implied in this press release are subject to other risks and uncertainties, including those discussed under the heading “Risk Factors” in G Medical’s prospectus filed pursuant to Rule 424(b)(4), filed with the Securities and Exchange Commission (“SEC”) on June 28, 2021, and in any subsequent filings with the SEC. Except as otherwise required by law, G Medical undertakes no obligation to publicly release any revisions to these forward-looking statements to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events. References and links to websites have been provided as a convenience, and the information contained on such websites is not incorporated by reference into this press release. G Medical is not responsible for the contents of third-party websites. Contact: G Medical Service +972 8-958-4777 service@gmedinnovations.com Contact Details G-Medical Innovations Holdings Ltd, Oren Cohen +972 8-958-4786 orenc@gmedinnovations.com Company Website https://gmedinnovations.com/

December 16, 2021 07:00 AM Eastern Standard Time

American Kidney Fund Activates Disaster Relief Program to Support Dialysis and Post-Transplant Patients Affected by Tornadoes in Six States

American Kidney Fund

, The American Kidney Fund (AKF) has activated its Disaster Relief Program to provide emergency grants to dialysis and post-transplant patients who were impacted by the devastating tornadoes on December 10 and 11. AKF’s Disaster Relief Program is the nation’s only rapid-response system that provides emergency financial assistance to dialysis and recent transplant patients. “We were devastated by the news of the tornadoes and our hearts go out to the communities impacted. Through our Disaster Relief Program, we will aid dialysis and post-transplant patients who were affected,” said LaVarne A. Burton, AKF President and CEO. “Our grants provide assistance when it is needed the most and help alleviate some of the financial and health concerns of patients who find themselves navigating the aftermath of a natural disaster.” Emergency grants of $250 are being made available for dialysis and post-transplant patients impacted by the tornadoes in Kentucky, Arkansas, Illinois, Mississippi, Missouri, and Tennessee. Disaster relief grants from AKF help patients replace lost medications and special renal diet foods, pay for temporary housing and transportation to treatment, and replace clothing and personal essentials lost due to the natural disaster or the need to evacuate without notice. AKF has been providing emergency disaster financial assistance to kidney patients throughout all the major disasters that have struck the United States and its territories for the past two decades. Earlier this year, AKF allocated $325,000 to more than 1,600 dialysis and post-transplant patients during the Texas winter storm crisis and $150,000 in emergency grants to more than 750 dialysis and kidney transplant patients affected by Hurricane Ida. AKF also activated its Coronavirus Emergency Fund in March 2020, providing over $3.1 million in assistance to nearly 13,000 dialysis and transplant patients during the pandemic. Dialysis and recent kidney transplant patients who need emergency financial help should contact a social worker at their dialysis clinic for information on applying for aid or apply directly at gms.KidneyFund.org. Applications will be accepted until Dec. 31. Charity Navigator has recognized AKF as one of the four-star charities providing emergency assistance in the aftermath of the tornadoes. AKF is covering the cost of processing and distributing grants, so that 100% of donations to the AKF Disaster Relief Program will be used to assist kidney patients affected by the tornadoes. ### About the American Kidney Fund The American Kidney Fund (AKF) fights kidney disease on all fronts as the nation’s leading kidney nonprofit. AKF works on behalf of the 37 million Americans living with kidney disease, and the millions more at risk, with an unmatched scope of programs that support people wherever they are in their fight against kidney disease—from prevention through transplant. With programs that address early detection, disease management, financial assistance, clinical research, innovation and advocacy, no kidney organization impacts more lives than AKF. AKF is one of the nation’s top-rated nonprofits, investing 97 cents of every donated dollar in programs, and holds the highest 4-Star rating from Charity Navigator and the Platinum Seal of Transparency from GuideStar. For more information, please visit KidneyFund.org, or connect with us on Facebook, Twitter, Instagram and LinkedIn. Contact Details American Kidney Fund Stefanie Tuck +1 202-470-1797 AKF@jpa.com Company Website https://www.kidneyfund.org/

December 15, 2021 10:30 AM Eastern Standard Time

Variational AI Partners with the University of British Columbia and adMare BioInnovations to Develop COVID-19 Therapeutic

Variational AI

Variational AI, developer of state-of-the-art generative AI technology to redefine the economics of drug development by accelerating the discovery of novel and optimized small molecule therapeutics, today announced the company has generated and ordered compounds for validation in partnership with the University of British Columbia (UBC) and adMare BioInnovations to develop a novel SARS-CoV-2 Main Protease (3CLpro) inhibitor. The therapeutic is intended to be efficacious against the wild type and current variants of concern, including Delta and potentially Omicron, in the form of an antiviral pill. The COVID-19 drug discovery program is funded by Canada’s Digital Technology Supercluster, which is supported by the Canadian Ministry of Innovation, Science and Industry. “The Variational AI team is honored to partner with the University of British Columbia and adMare BioInnovations to work to address this most urgent medical need,” said Handol Kim, co-founder and CEO, Variational AI. “As society continues to grapple with COVID-19 variants, it is more important than ever to leverage the power of machine learning to accelerate our drug discovery efforts.” Variational AI has trained its generative AI algorithm on a large amount of COVID-19 data to generate new molecules and has ordered a number of compounds to be synthesized that are predicted to be potent and safe with fewer side effects. Variational AI uses a generative model known as Variational Autoencoder (VAE), which is able to optimize molecular properties more quickly and uses data far more efficiently. The company intends to license the antiviral compound to a partner to accelerate progress and get the therapeutics into clinics sooner. “We are proud to support Variational AI’s innovative approach to discovering an effective therapeutic for COVID-19,” said Sue Paish, CEO of the Digital Technology Supercluster. “While vaccines offer the first and best line of defense against COVID-19, the global community needs as many therapeutic options as possible to prevent fatalities and improve patient outcomes.” Generally, pills can be manufactured, distributed and stored more easily and cost-effectively than vaccines and are particularly well-suited to treat people in developing countries. In addition to COVID-19 and its variants, the resulting therapeutic may also be efficacious against other coronaviruses. “Our lab is committed to remaining at the forefront of applying computational methods to discover COVID-19 therapeutics, and our collaboration with Variational AI to leverage the company’s powerful AI adds a promising pipeline of novel and potent SARS-CoV-2 Main Protease inhibitors to the arsenal of antiviral options,” said Artem Cherkasov, Ph.D., professor of medicine, University of British Columbia. About Variational AI Variational AI uses state-of-the-art machine learning in a data-efficient method to rapidly generate novel and diverse compounds that are optimized for multiple properties to avoid the most common causes of drug attrition and increase clinical probability of success. Variational AI works with leading biopharmaceutical partners and is developing its own internal pipeline. To learn more, visit https://variational.ai. Contact Details Sage Morander +1 401-490-9700 variationalai@svmpr.com Company Website https://variational.ai/

December 15, 2021 10:00 AM Eastern Standard Time

Oncotelic’s Dr. Anthony Maida to Present at 2nd Annual TGF-β for Immuno-Oncology Drug Development Summit in January 2022

Oncotelic Therapeutics

Oncotelic Therapeutics, Inc. ("Oncotelic" or the "Company") (OTCQB:OTLC), a leading developer of TGF-β therapeutics for oncology and virology, today announced that the Company’s Chief Clinical Officer and Board Director, Dr. Anthony Maida, will present at the upcoming 2 nd Annual TGF-β for Immuno-Oncology Drug Development Summit ( tgf-beta-summit.com ), which will take place virtually from January 25, 2022 to January 27, 2022. “There is significant worldwide interest in the clinical application of anti-TGF-β inhibitors, in combination with checkpoint inhibitors, as well as other immuno-oncology and chemotherapeutic options. We look forward to sharing the clinical promise of OT-101 in this setting.” noted Dr. Anthony Maida, Chief Clinical Office – Translational Medicine. TGF-β has been recognized by drug developers, for many years, as holding vast therapeutic potential due to its vital role in cell functioning and signaling. But its complex nature and its ability to be both tumor promoting and tumor suppressing has presented many obstacles for the industry. However, the field appears to be at a tipping point at present, with more candidates moving through clinical evaluation, pointing to an explosion of new data on the way. “I am excited that we have the opportunity to join other professionals in the field in January to explore novel insights into targeting TGF-β from discovery through clinical testing, and to learn from fellow colleagues such as Genentech, AbbVie, Takeda, and Mestag Therapeutics.” noted Dr. Vuong Trieu, CEO and Chairman of Oncotelic. OT-101 is a first-in-class anti-TGF-β ribonucleic acid (“RNA”) therapeutic that has exhibited single agent activity in relapsed/refractory cancer patients in multiple clinical trials. OT-101 has also demonstrated activity against the SARS-CoV-2 virus, the virus that causes COVID-19, and is currently being evaluated in the Company’s C001 clinical trial against hospitalized severe COVID-19 patients. Both tumor cells and SARS-Cov-2 induce TGF-β as part of their immune evasion mechanism. Consequently, inhibiting TGF-β through therapeutic use of OT-101 carries significant potential to help both cancer and COVID patients in the future. Recent analyst report for Oncotelic can be accessed here: http://www.hillsresearch.com/wp-content/uploads/2021/12/OTLC-3Q21.pdf Recent Dr. Anthony Maida interview on our clinical program can be accessed here: https://www.asbestos.com/news/2021/12/07/mesothelioma-trial-covid-19-drug/ About Oncotelic Therapeutics Oncotelic Therapeutics, Inc. (f/k/a Mateon Therapeutics, Inc.) ("Oncotelic"), was formed in the State of New York in 1988 as OXiGENE, Inc., was reincorporated in the State of Delaware in 1992, and changed its name to Mateon Therapeutics, Inc. in 2016, and Oncotelic Therapeutics, Inc. in November 2020. Oncotelic is an artificial intelligence driven immuno-oncology company with a robust pipeline of first in class TGF-β immunotherapies for late stage cancers such as gliomas, pancreatic cancer and melanoma. OT-101, the lead immuno-oncology drug candidate of Oncotelic, is a first-in-class anti-TGF-β RNA therapeutic that exhibited single agent activity in relapsed/refractory cancer patients. OT-101 also has shown activity against SARS-CoV-2 and has completed a phase 2 trial against COVID-19 with data cleaning and datalock ongoing. Oncotelic is seeking to leverage its deep expertise in oncology drug development to improve treatment outcomes and survival of cancer patients with a special emphasis on rare pediatric cancers. Oncotelic also has rare pediatric designation for DIPG (OT-101), melanoma (CA4P), and AML (OXi 4503). The Company also acquired PointR Data Inc. ("PointR") in November 2019. For more information, please visit www.oncotelic.com Oncotelic Therapeutics, Inc. ("Oncotelic" or the "Company") (OTCQB:OTLC), a leading developer of TGF-beta therapeutics for oncology and virology This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements, other than statements of historical facts, included in this communication regarding strategy, future operations, future financial position, prospects, plans and objectives of management are forward-looking statements. Words such as "may", "expect", "anticipate", "hope", "vision", "optimism", "design", "exciting", "promising", "will", "conviction", "estimate," "intend," "believe", "quest for a cure of cancer", "innovation-driven", "paradigm-shift", "high scientific merit", "impact potential" and similar expressions are intended to identify forward-looking statements. Forward looking statements contained in this press release include, but are not limited to, statements about future plans, the progress, timing, clinical development, scope and success of future clinical trials, the reporting of clinical data for the company's product candidates and the potential use of the company's product candidates to treat various cancer indications. Each of these forward-looking statements involves risks and uncertainties, and actual results may differ materially from these forward-looking statements. Many factors may cause differences between current expectations and actual results, including unexpected safety or efficacy data observed during preclinical or clinical studies, clinical trial site activation or enrollment rates that are lower than expected, changes in expected or existing competition, changes in the regulatory environment, failure of collaborators to support or advance collaborations or product candidates and unexpected litigation or other disputes. These risks are not exhaustive, the company faces known and unknown risks, including the risk factors described in the Company's annual report on Form 10-K filed with the SEC on April 15, 2021 and in the company's other periodic filings. Forward-looking statements are based on expectations and assumptions as of the date of this press release. Except as required by law, the company does not assume any obligation to update forward-looking statements contained herein to reflect any change in expectations, whether as a result of new information future events, or otherwise. Contact Details Amit Shah ashah@oncotelic.com Company Website https://www.oncotelic.com

December 14, 2021 09:01 AM Eastern Standard Time

1 ... 241 242 243 244 245 ... 302